MVT: In the News

December 4, 2025 — Salt Lake City, UT  — The Nucleus Institute’s investment committee has unanimously approved and completed an investment in Microvascular Therapeutics Inc. (MVT) through MVT’s convertible note. “This is our first institutional investor,” said Dr. Evan Unger, MD, CEO and Founder of MVT. “Their support is a strong validation of our investor readiness following Nucleus’ extensive due diligence.” “We are currently planning a priced round to fund a Phase III clin

Salt Lake City, UT –Wednesday November, 5 th  2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT) will be presenting new preclinical data demonstrating that focused ultrasound (FUS) using proprietary phase-shift microbubbles, NanoBlate (MVT-101), can selectively ablate brain tumors and open the blood-brain barrier (BBB) in targeted regions, potentially enabling safer, more precise, and non-invasive treatment for patients with malignant brain tum

Phase‑shift microbubble (also known as nanobubble) technology demonstrates robust thrombus resolution in a porcine deep vein thrombosis (DVT) model. Salt Lake City, UT – Microvascular Therapeutics, Inc. (MVT) today announced the publication of compelling preclinical data demonstrating that its proprietary phase‑shift microbubble platform, MVT‑101 (Solv), significantly enhances sonothrombolysis in a clinically relevant porcine model of deep vein thrombosis (DVT). The study app

Chicago, IL – October 7th, 2025 – Microvascular Therapeutics (MVT), a clinical-stage biopharmaceutical company pioneering innovations in...